The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province

• Conditions: Gastric Cancer

• Registration Number: NCT03478943
• Lead Sponsor: Henan Cancer Hospital

Brief Summary

The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01-30
• Study First Submitted: 2018-03-20
• Study First Submitted QC: 2018-03-20
• Study First Posted: 2018-03-27
• Status Verified: 2020-05
• Last Update Submitted: 2020-05-26
• Last Update Posted: 2020-05-28
• Primary Completion: 2020-08-01
• Study Completion: 2020-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Male or female patients .
2. Confirmed by Pathology or histology of Gastric cancer.
3. Patients should be voluntary to the trial and provide with signed informed consent.
4. The researchers believe patients can benefit from the study.

Exclusion Criteria

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories.
2. Pregnant or lactating women.
3. Patients with Apatinib contraindications.
4. Patients of doctors considered unsuitable for the trial.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free surviva	1 year
Progress free survival	1 year

Secondary Outcome Measures

Name	Time	Method
overall survival	3 year
Objective Response Rate	1 year
Disease Control Rate	1 year

Trial Locations

Locations (1)

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China